NCT00536588View on ClinicalTrials.gov

A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Bladder Neoplasms
Interventions
GENETIC

SCH 721015 with SCH 209702

Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00536588 - A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) | Biotech Hunter | Biotech Hunter